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Background: Perinatal asphyxia is a severe clinical condition affecting around four million newborns worldwide. 
It consists of an impaired gas exchange leading to three biochemical components: hypoxemia, hypercapnia and 
metabolic acidosis.
Methods: The aim of this longitudinal experimental study was to identify the urine metabolome of newborns 
with perinatal asphyxia and to follow changes in urine metabolic profile over time. Twelve babies with perinatal 
asphyxia were included in this study; three babies died on the eighth day of life. Total-body cooling for 72 hours 
was carried out in all the newborns. Urine samples were collected in each baby at birth, after 48 hours during 
hypothermia, after the end of the therapeutic treatment (72 hours), after 1 week of life, and finally after 1 month 
of life. Urine metabolome at birth was considered the reference against which to compare metabolic profiles in 
subsequent samples. Quantitative metabolic profiling in urine samples was measured by gas chromatography mass 
spectrometry (GC-MS). The statistical approach was conducted by using the multivariate analysis by means of 
principal component analysis (PCA) and orthogonal partial least square discriminant analysis (OPLS-DA). Pathway 
analysis was also performed.
Results: The most important metabolites depicting each time collection point were identified and compared 
each other. At birth before starting therapeutic hypothermia (TH), urine metabolic profiles of the three babies died 
after 7 days of life were closely comparable each other and significantly different from those in survivors.
Conclusions: In conclusion, a plethora of data have been extracted by comparing the urine metabolome at 
birth with those observed at each time point collection. The modifications over time in metabolites composition 
and concentration, mainly originated from the depletion of cellular energy and homeostasis, seems to constitute a 
fingerprint of perinatal asphyxia.
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Introduction
Perinatal asphyxia was previously defined as severe lack of 
oxygen and perfusion to the fetus, especially in the fetal 
brain, around the time of birth (1). Over the last decades, 
terms as perinatal asphyxia, birth asphyxia, fetal distress, 
hypoxic-ischemic encephalopathy (HIE) have been replaced 
with an “umbrella term”: neonatal death associated with 
acute intrapartum events (2). This change was promoted 
by several consensus statements on the basis of a paradigm 
shift in the epidemiologic measurement of intrapartum 
injury: from process-based or symptom-based indicators to 
outcome-based measures of mortality and acute morbidity. 
Unfortunately, the “umbrella term” is long and not user-
friendly and thus conventional terms are yet widely used 
in the literature and in clinical practice. Perinatal asphyxia 
can be fatal; it is yet one of the primary causes of early 
neonatal mortality worldwide, affecting 4 million babies per 
year and causing the death of around 1 million subjects (3). 
In survivors, brain injuries due to HIE lead to severe 
disability (4); indeed, the lack of oxygen involves primarily 
brain, heart, kidney, lung, and gut causing organ injuries 
and permanent damages (5). The timing of the organ insult 
is a key factor influencing the extension and the pattern of 
the damage and, in turn the clinical outcome. The brain is 
the most injured organ by perinatal asphyxia (6); almost all 
of the oxygen consumed by the human brain is utilized for 
the oxidation of glucose, which in turn is the only significant 
substrate for energy in cerebral metabolism. In detail, 
the aerobic glycolysis generates pyruvate; subsequently, 
pyruvate enters into the citric acid cycle, also known as the 
tricarboxylic acid (TCA) cycle or the Krebs cycle, within 
mitochondria, ultimately generating adenosine triphosphate 
(ATP). Neonatal hypoxic/ischemic events remarkably 
modify these biochemical pathways, leading to energy 
failure due to: shift from aerobic to anaerobic metabolism; 
mitochondrial injury with a reduced ATP production; lactate 
accumulation; over-production of reactive oxygen species 
(ROS); decreased protein phosphorylation (7,8). As a result, 
all the energy-dependent mechanisms reduce their activities, 
leading to neuronal depolarization, cell swelling, and loss 
of cell homeostasis (9). Depending on various factors, such 
as the severity of injury and the early retrieval of cerebral 
blood flow, several neurons may recover their functions by 
reversing the chemical gradient and restoring the integrity 
of the membrane. Conversely, other neurons lose completely 
their functions and interconnections. Current evidences 
suggest that perinatal asphyxia can alter gene expression, 
inducing epigenetic changes in DNA methylation, histone 
modifications and modifying the rate of noncoding RNA 
synthesis (10); in addition, the response to asphyxia depends 
on genetic and epigenetic key factors, integrated each 
other (11,12). Therapeutic hypothermia (TH), a brain 
cooling technique, usually maintained over 72 hours after 
the hypoxic-ischemic event, has gained consensus for the 
treatment of perinatal asphyxia and HIE, reducing the 
mortality rate and long-term neurodevelopmental disabilities 
at 12–24 months of age (13,14). TH induces a slowdown 
in cerebral metabolism of approximately 5% every one 
degree fall in temperature, delaying the onset of anoxic cell 
depolarization (15). Unfortunately, despite TH treatment 
several children continue either to die or to suffer moderate-
severe handicaps. Therefore, there is the need to investigate 
changes in molecular pathways during perinatal asphyxia and 
TH; the holistic approach offers two advantages over existing 
methods: comprehensiveness and complementarity (16). 
Metabolomics, one of the youngest ‘omics’ disciplines, 
encompasses comprehensive metabolites evaluation, pattern 
recognition, and statistical analysis, with the intent to identify 
and quantify metabolites related with a physiological or a 
pathological process (17,18). Emerging studies on animal 
model have highlighted the importance to recognize the 
metabolic fingerprint in perinatal anoxia-hypoxia (19-21). 
In newborns with perinatal asphyxia, a small number of 
metabolomics studies have been published in the literature 
(22-27); each of them has depicted the metabolic snapshot of 
the disease. As recapitulated in a recent review (28), human 
metabolomics studies have found that the most impaired 
molecular pathway during perinatal asphyxia and TH are the 
TCA cycle and the osmoregulation system.
The aim of this longitudinal experimental study was to 
identify the urine metabolome of newborns with perinatal 
asphyxia at birth (Time 0, T0), corresponding to the 
admission to the neonatal intensive care unit (NICU) and 
then to follow changes in urine metabolic profile over time: 
at 48 hours, during the TH (T1); at the end of the TH 
(T2, corresponding to 72 hours); after 1 week (T3); after 
1 month (T4). The experimental design has been plotted in 
Figure 1.
Methods
Patients population
We included 12 newborns (11 full-terms and one preterm) 
with perinatal asphyxia, admitted in the NICU of S. Croce 
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e Carle hospital, Cuneo, Italy. Their main demographic and 
clinical characteristics are summarized in Table 1. The study 
was approved by institutional ethics board of Cagliari (CA-
206-18/03/2013); parents gave written informed consent to 
the study. Asphyxia diagnosis was performed by using the 
Sarnat grading scale (Sarnat staging), based on the infant’s 
clinical findings and neurologic signs (29). All the babies 
were treated with hypothermia over 72 hours; urine samples 
were collected at different time points. The time sequence 
of samples collection was: at birth, when they were admitted 
to the NICU (T0); after 48 hours (T1); after 72 hours (T2); 
after 1 week (T3); after 1 month (T4). Neurodevelopmental 
outcome was evaluated later, at one year of age by using the 
Bayley Scales of Infant and Toddler Development (cognitive, 
language, motor function, social-emotional, adaptive 
behaviour scale)—3rd Edition (Bayley-III) (30).
Samples collection, storage and preparation
The overall number of urine samples collected from 
12 newborns over the first month of life was 43; such 
samples were not available (dead babies), while others were 
insufficient for analysis or missed (vial breakage during 
transport or centrifugation), as detailed in Table 2. Each 
urine sample (volume around 2–3 mL) was collected by a 
non-invasive method: a ball of cotton was inserted into the 
disposable diaper; then urine was aspired with a syringe 
and transferred to a sterile 2 mL vial. After collection, 
all the vials were centrifuged and supernatants were 
immediately frozen and stored at –80 ℃ until analysis. 
Sample preparation before analysis consisted of a multi-
step procedure. Firstly, urine samples were thawed at room 
temperature and homogenized by using a vortexer for 
5–10 seconds. Secondly, 150 μL were transferred into a 
tube, where 800 μL of urease solution (1 mg/mL) were 
added. The resulting solution was sonicated for 30 minutes; 
at the end of the process, 800 μL methanol were further 
added. After sample centrifugation, 1,200 μL of supernatant 
were transferred into a glass vial and dried in a vacuum 
centrifuge overnight. Subsequently, 30 μL of a 0.24 M 
solution of methoxylamine hydrochloride in pyridine were 
added to each vial; samples were further mixed by vortexer 
and kept at room temperature over 17 hours. Finally, 30 μL 
of N-methyl-N-trimethylsilyltrifuoroacetamide (MSTFA) 
were added, mixed for 1 min by vortexer and kept 1 hour 
at room temperature. The derivatized samples were diluted 
with 600 μL of a tetracosane solution (internal standard) in 
hexane (0.01 mg/mL) just before GC-MS analysis.
Samples analysis and data processing
The derivatized samples were analyzed by using a global 
unbiased mass spectrometry-based platform with GC-
MS incorporating an Agilent 5975C interfaced to the GC 
7820 (Agilent Technologies, Palo Alto, CA, USA). The 
system was equipped with a DB-5ms column (Agilent J&W 
Scientific, Folsom, CA, USA); the injection temperature 
was set at 230 ℃ and the detector temperature at 280 ℃. 
Carrier gas (helium) flow rate was equal to 1 mL/min. 
GC oven starting temperature program was 90 ℃ with 
1 min hold time and ramping at a rate of 10 ℃ per minute, 
reaching a final temperature of 270 ℃ with 7 min hold time. 
1 μL of the derivatized sample was injected in split (1:20) 
mode. After a solvent delay of 3 min, mass spectra were 
acquired in full scan mode using 2.28 scans per second, with 
a mass range of 50–700 Amu. Each acquired chromatogram 
was analyzed by means of the free software Automated 
Mass Spectral Deconvolution and Identification System 
(AMDIS): http://chemdata.nist.gov/mass-spc/amdis. Each 
peak was identified by comparing the corresponding mass 
spectra and retention times with those stored in an in-house 
made library including 255 metabolites. Other metabolites 
were identified by using the National Institute of Standards 
and Technology’s mass spectral database (NIST08) (31) and 
Figure 1 Plot of the experimental design. Red dots indicate the urine collection points.
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the Golm Metabolome Database (GMD) (32). As a result, 
122 compounds were accurately identified, whereas 
5 additional metabolites were tentatively identified on the 
basis of GMD data. AMDIS analysis produced a matrix 
spreadsheet (Microsoft Excel®, Microsoft Co, Redmond, 
WA, USA) as a preliminary tool for the subsequent 
chemometric analysis.
Data modeling and statistical analysis
Data were analyzed by applying both the unsupervised and 
the supervised multivariate statistical approach. Principal 
component analysis (PCA), the most commonly used 
unsupervised method (33), was applied to identify specific 
structures such as clusters, anomalies or trends in a dataset 
(34,35). Partial least squares-discrimination analysis (PLS-
DA) and orthogonal partial least square discriminant 
analysis (OPLS-DA) were applied as supervised methods to 
identify important variables with discriminative power (36). 
OPLS-DA is a data visualization method for the observation 
of grouping within multivariate data. This supervised 
analysis employs linear regression, including the class 
memberships of the samples in the calculation. OPLS is 
able to rotate the projection, so that the model focuses on 
the side corresponding to the effect of interest; the result is 
a clearer group’s separation and discrimination. The validity 
of the OPLS-DA model is assessed by statistical parameters: 
the correlation coefficient R2, and the cross-validation 
correlation coefficient Q2. PLS-DA and OPLS-DA were 
computed by using the Soft Independent Modeling of Class 
Analogy software package (SIMCA, version 13.0, Umetrics, 
Umea, Sweden) (37). By the supervised analysis we obtained 
the set of variables importance on partial least squares 
projections (VIP). The VIP method selects variables by 
calculating the VIP score for each variable and excluding all 
the variables with VIP score below 1, a predefined threshold 
(38). In this study, VIP are those metabolites better 
characterizing each group. Receiver operating characteristic 
(ROC) analysis was done for each biomarker, being the 
method of choice for evaluating biomarker specifications. 
Ultimately, pathway topology analysis was performed for 
each of the four time collection points, assuming that the 
upstream nodes regulated the downstream nodes, and not 
vice versa. The resulting “metabolome view” depicted 
all metabolic pathways arranged according to the scores 
from the enrichment analysis (y-axis) and from topology 
analysis (x-axis), by using Metaboanalyst 3.0 (39). The goal 
of pathway analysis was to identify pathways significantly 
impacting in a given phenotype. Since many pathways were 
tested simultaneously, P values were adjusted for multiple 
testing. Concisely, the total value corresponds to the total 
number of compounds involved in a pathway; the hits value 
Table 2 Samples collection map over time
Patient IDEE U0 U1 U2 U3 U4
001 Y Y Y Y Y
002 Y Y Y Y Y
003 Not available Y Y Y Insufficient
004 Y Y Y Death Not available
005 Y Y Y Y Y
006 Y Y Y Insufficient Missed
007 Y Y Missed Y Insufficient
008 Y Y Y Insufficient Not available
009 Y Y Missed Y Insufficient
010 Y Y Y Death Not available
011 Y Y Y Missed Y
012 Y Y Y Death Not available
U0, U1, U2, U3, U4, urine samples collected at T0 (birth), T1 (48 h after birth), T2 (72 h after birth), T3 (1 week after birth), and T4 (1 month 
after birth), respectively; Y, available, eligible sample.
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is the actually matched number from the user uploaded 
data; the raw P value is the original P value calculated by 
the enrichment analysis; the Holm P value is the P value 
adjusted by the Holm-Bonferroni method; the impact value 
represents the metabolic pathway impact calculated from 
pathway topology analysis (40). 
Results
Out of the 12 newborns enrolled in this study, 3 babies 
(patient IDEE: U004, U010 and U012) died during the 
7th day of life. All the deaths were attributable to HIE and 
comorbid conditions, as reported in Table 1. In all of the 
remaining nine babies, results obtained by using the Bayley 
III demonstrated the absence of any neurodevelopmental 
abnormality. The unsupervised PCA was applied to offer 
a global view on changes over time in urine metabolomics 
profile. Based on the two principal components (R2X 
=0,65; Q2 =0,36), the resulting plot highlights a “trend in 
migration” of the metabolic profile for each baby, from T0 
to T4 (Figure 2); however, the extent of any change and its 
direction depend on various factors: clinical variables (e.g., 
prematurity); presence/absence of comorbid conditions (e.g., 
MODS); clinical outcome (e.g., death). The supervised 
OPLS-DA model originated a clear separation between 
metabolic profiles at birth and each of those corresponding 
to samples collection, as reported in Figure 3. Urine 
metabolome at birth (before starting TH) was considered 
the reference against which to compare urine metabolome 
after 48 hours, 72 hours, 1 week and 1 month. Based on 
the VIP score >1, potential metabolites were identified 
for each model: after 48 hours, 4 metabolites were found 
increased and 54 metabolites decreased compared to birth; 
after 72 hours, 22 were increased and 29 decreased; after 
1 week, 24 increased and 19 decreased; after 1 month 
5 increased and 33 decreased. To make more significant 
and comprehensible these results, we reported a partial list 
of metabolites including those with a continuous trend in 
changes over time (Figure 4). Following this strategy, lactic 
acid, taurine, lysine, and mannitol decreased systematically 
from birth; conversely, lactose increased from T1 to T3 
when compared with T0, as well as citric acid and galactose 
from T2 to T4. For each metabolite the area under the 
curve (AUC) ROC was also calculated. In detail, lactic acid 
AUC: T1 =0.74, T2 =0.75, T3 =1.0, T4 =0.87. Taurine 
AUC: T1 =0.66, T2 =0.70, T3 =0.98, T4 =0.91. Lysine 
AUC: T1 =0.62, T2 =0.65, T3 =0.67, T4 =0.83. Mannitol 
AUC: T1 =0.65, T2 =0.65, T3 =0.67, T4 =0.87. Lactose 
AUC: T2 =0.65, T3 =1.0. Citric acid AUC: T2 =0.90, T3 
=0.98, T4 =0.97. Other metabolites did not increase or 
decrease constantly over time. Surprisingly, the unknown 
metabolite U1710 increased in T1 (AUC =0.82) and T2 
(AUC =0.82) and decreased in T3 (AUC =0.80) and in T4 
(AUC =0.74), when compared with T0. The most relevant 
result is the significant difference between the urinary 
metabolome of the three babies died after 7 days of life and 
that of survivors. Notably, this remarkable difference was 
found at birth before the start of TH and was confirmed at 
the end of therapy, at 72 hours of life, as showed in Figure 5. 
Pathway analysis revealed the most affected metabolic 
pathways by perinatal asphyxia, as reported in Figures 6 and 
7. Among the 43, 31, 45, 43, and 40 pathways recognized 
at birth, 48, 72 h, 1 week, and 1 month of life, respectively, 
we reported the ten most important metabolic pathways for 
each time point. The pathways ranking is based on indexes 
described above: total value, hits value, raw P value, Holm 
P value, and impact value. During TH (samples collected at 
48 and 72 hours, T1 and T2) the most impacting pathways 
on both molecular phenotypes were: phenylalanine 
metabolism, fructose and mannose metabolism, pyrimidine 
metabolism, glycolysis or gluconeogenesis, starch and 
sucrose metabolism, pentose phosphate pathway. After 
1 week, molecular phenotype shared four pathways with that 
Figure 2 PCA score plot derived from the GC-MS analysis of 
urine samples in 12 newborns with perinatal asphyxia over the first 
month of life. T0 = birth (start of TH); T1 =48 hours after birth; 
T3 =72 hours after birth (end of the TH); T3 =1 week after birth; 
T4 =1 month after birth. PCA, principal component analysis.
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at birth: tyrosine metabolism, phenylalanine, tyrosine and 
tryptophan biosynthesis, ubiquinone and other terpenoid-
quinone biosynthesis, nitrogen metabolism. Finally, at 
1 month of life we found a consistent shift of the metabolic 
phenotype: among the first ten pathways, eight were not 
included previously.
Discussion
Perinatal asphyxia causes an imbalance in homeostasis of 
biological systems consisting of perturbation in gene 
expression and, in turn, in cellular activity. Metabolites 
represent the molecular endpoint or phenotype of the 
interplay between environment and gene expression and 
thus metabolomics offers a holist approach for the early and 
accurate evaluation of changes in dynamics of biological 
systems. Our results clearly suggest a dynamic change over 
time in urine metabolome of babies with perinatal asphyxia 
treated with hypothermia. In this study urine metabolome 
at birth, before the start of TH, was considered as landmark 
and no control group was selected and used as reference 
against which to compare results found in babies with 
perinatal asphyxia. In fact, it is reasonable to assume that in 
a NICU no baby can be considered “healthy”; moreover, 
hypoxia, ischemia and anoxia are commonly associated with 
several neonatal pathological conditions requiring intensive 
care. Accordingly, there is a high likelihood to include 
babies with asphyxia within a hypothetic “control group”. 
Finally, information originating from the comparison of 
urine metabolome over time in babies with perinatal 
asphyxia is clinically more relevant and useful rather than 
the simple comparison with a theoretical control group. 
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Figure 3 OPLS-DA of urine metabolic profile in perinatal asphyxia. Scores plot of the comparison of urine samples at birth before starting 
TH (T0, black dots) with: urine samples after 24 hours from birth, during TH (T1, gray dots, A); urine samples after 72 hours from birth, 
at the end of TH (T2, brown dots, B); urine samples after 1 week from birth (T3, yellow dots, C); urine samples after one month from birth 
(T4, purple dots, D). The X axes is the weighted score component t[1] whereas the Y axes is the orthogonal weighted score component t[1]. 
OPLS-DA, orthogonal partial least squares-discriminant analysis; TH, therapeutic hypothermia. 
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T1 vs. T0 T2 vs. T0 T3 vs. T0 T4 vs. T0
Increased Decreased Increased Decreased Increased Decreased Increased Decreased
Lactose Lactic acid Lactose Lactic acid Lactose Lactic acid Lactic acid
Taurine Citric acid Taurine Citric acid Taurine Citric acid Taurine
Lysine Galactose Lysine Galactose Lysine Galactose Lysine
Mannitol Creatinine Mannitol Creatinine Mannitol Mannitol
Oxalic acid 4-Hydroxyproline 4-Hydroxyproline Oxalic acid Oxalic acid
Fructose Fructose Fructose
N-Acetyl-glucosamine N-Acetyl-glucosamine Galactitol Galactitol N-Acetyl-glucosamine
Kynurenic acid Kynurenic acid Kynurenic acid
Sedoheptulose Sedoheptulose Sedoheptulose
Ethanolamine Ethanolamine Ethanolamine
Sucrose Sucrose Sucrose
5-(Acetylamino)-
3,5-dideoxy-D-
glycero-galacto-2- 
nonulosonic acid
5-(Acetylamino)-3,5-
dideoxy-D-glycero-
galacto-2- nonulosonic 
acid
5-(Acetylamino)-
3,5-dideoxy-D-
glycero-galacto-2- 
nonulosonic acid
Scylloinositol Scylloinositol Scylloinositol
U1605 U1605 U1605
U1455 U1455 U1455
Monosacch. E Monosacch. E Monosacch. E
U1710 U1710 U1710 U1710
Figure 4 Most relevant changes in metabolites concentration over time in perinatal asphyxia. Urine metabolome at birth has been assumed 
as reference. T0, birth; T1, 48 hours; T2, 72 hours; T3, 1 week; T4, 1 month. Unknown metabolites are listed as: U1455, U1605, U1710 
and Monosacch. E.
Figure 5 PLS-DA of urine metabolome at birth, before starting TH (A) and after 72 hours, at the end of therapy (B). In this plot, PLS-DA 
enables class separation (discrimination) analysis between survivors and died newborns. PLS-DA, partial least squares-discriminant analysis; 
TH, therapeutic hypothermia.
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Figure 6 Metabolic pathway analysis at birth (A), after 24 hours from birth (B), after 72 hours (C), and after 1 week of life (D). Metabolic 
pathways are represented as circles according to their scores from enrichment (vertical axis) and topology analyses (pathway impact, 
horizontal axis). Darker circle colors indicate more significant changes of metabolites in the corresponding pathway. The size of the circle 
corresponds to the pathway impact score and is correlated with the centrality of the involved metabolites. A list of ranked pathways 1–10 
based on their relevance to the given traits is reported on the left of each panel; corresponding numbers have been associated with symbols 
in the plots.
Figure 7 Metabolic pathway analysis after 1 month of life. Metabolic pathways are represented as circles according to their scores from 
enrichment (vertical axis) and topology analyses (pathway impact, horizontal axis). Darker circle colors indicate more significant changes 
of metabolites in the corresponding pathway. The size of the circle corresponds to the pathway impact score and is correlated with the 
centrality of the involved metabolites. A list of ranked pathways 1–10 based on their relevance to the given traits is reported on the left; 
corresponding numbers have been associated with symbols in the plot.
1 Vitamin B6 metabolism
2 Alanine, aspartate and 
glutamate metabolism
3 Lysine biosynthesis
4 Histidine metabolism
5 D-Glutamine and 
D-glutamate metabolism
6 Butanoate metabolism
7 Pyrimidine metabolism
8 Glycine, serine and threonine 
metabolism
9 Primary bile acid biosynthesis
10 Lysine degradation
−
lo
g 
(p
)
Pathway impact
0.40.30.20.10.0
6
5
4
3
2
1
0
A B
C D
1 Taurine and hypotaurine metabolism
2 Tyrosine metabolism
3 Phenylalanine, tyrosine and 
tryptophan biosynthesis
4 Ubiquinone and other terpenoid-
quinone biosynthesis
5 Glycerolipid metabolism
6 Nitrogen metabolism
7 Purine metabolism
8 Primary bile acid biosynthesis
9 Fatty acid metabolism
10 Fatty acid elongation in 
mitochondria
1 Phenylalanine metabolism
2 Fructose and mannose 
metabolism
3 Pyrimidine metabolism
4 Fatty acid biosynthesis
5 Fatty acid metabolism
6 Fatty acid elongation in 
mitochondria
7 Glycolysis or Gluconeogenesis
8 Pentose and glucuronate 
interconversions
9 Starch and sucrose 
metabolism
10 Pentose phosphate pathway
1 Tryptophan metabolism
2 Phenylalanine, tyrosine and 
tryptophan biosynthesis
3 Tyrosine metabolism
4 Ubiquinone and other 
terpenoid-quinone 
biosynthesis
5 Fructose and mannose 
metabolism
6 Thiamine metabolism
7 Nitrogen metabolism
8 Phenylalanine metabolism
9 Galactose metabolism
10 Aminoacyl-tRNA biosynthesis
1 Pyrimidine metabolism
2 Glycolysis or 
Gluconeogenesis
3 Starch and sucrose 
metabolism
4 Galactose metabolism
5 Pentose phosphate pathway
6 Phenylalanine metabolism
7 Glycerolipid metabolism
8 Pyruvate metabolism
9 Fructose and mannose 
metabolism
10 Tyrosine metabolism
−
lo
g 
(p
)
−
lo
g 
(p
)
−
lo
g 
(p
)
−
lo
g 
(p
)
Pathway impact
Pathway impact Pathway impact
Pathway impact
0.40.30.3 0.20.2 0.1
0.05 0.050.15 0.150.25 0.250.10 0.100.20 0.200.30
0.1 0.0
0.0 0.0
0.0
6
5
4
3
2
1
0
3
2
1
0
1.5
1.0
0.5
0.0
2.5
2.0
1.5
1.0
0.5
0.0
© Annals of Translational Medicine. All rights reserved. Ann Transl Med 2016;4(21):417atm.amegroups.com
Noto et al. Metabolomics in perinatal asphyxiaPage 10 of 14
Several discriminant metabolites have been found 
persistently decreasing (lactic acid, taurine, lysine and 
mannitol) or increasing (citric acid, lactose and galactose) 
over time (Figure 4). The decrement of lactic acid over time 
from T1 to T4 in our population reflects the progressive 
recovery of aerobic metabolism. Notably, lactic acid was 
found significantly increased in the three dead babies, both 
in T0 and T2 (AUC 0.86 and 0.62, respectively). The role 
of lactic acid in the developing brain is that of an 
exchangeable substrate between astrocytes, the more 
abundant neuroglial cell type, and neurons; it is both a 
precursor of lipids and energy source for neurons. During 
hypoxia-anoxia, astrocytes consistently increase the lactic 
acid production rate by the activation of the anaerobic 
glycolysis pathway, with a progressive accumulation of this 
metabolite and, in turn, acidosis. The latter exerts a negative 
impact on astrocyte metabolism, leading to serious and 
irreversible astrocytes damage and cytolysis (41). The 
progressive loss in astrocytes number originates a redox 
imbalance caused by a massive generation of ROS and 
ultimately an additional damage to neurons, previously 
injured by the loss of energy source deriving from 
astrocytes. Our results confirm previous reports on the role 
of lactic acid as biomarker of poor outcome in perinatal 
hypoxia and HIE (42). Similarly to lactic acid, taurine 
(2-aminoethanesulfonic acid) decreased over time from T1 
to T4 and was found increased in T2 in the group of dead 
babies (AUC =0.86).  Taurine is  synthesized from 
methionine and cysteine in the presence of vitamin B6. This 
metabolite is involved in the maintenance of intracellular 
sodium and calcium homeostasis and in the balance of 
neurotransmitters. In addition, taurine and its analogues 
exert anti-neurotoxic and anti-inflammatory effects (43). 
Being an intracellular metabolite, alterations in plasma 
membrane permeability and cytolysis give rise to the 
accumulation of extracellular taurine and therefore it may 
be considered a biomarker of cellular injury and death. As a 
consequence, the decrease over time in urinary taurine 
concentration can be explained by the progressive recovery 
of injured tissues and organs. Conversely, the high taurine 
urinary level in the group of dead babies may be considered 
an index of cell necrosis and death due to hypoxia. In a 
p r e v i o u s  m e t a b o l o m i c s  s t u d y  o n  b a b i e s  w i t h 
bronchopulmonary dysplasia (BPD) performed by proton 
nuclear magnetic resonance (1H NMR), taurine showed a 
closely comparable behavior to that found in this study, 
confirming the key role of this metabolite in predicting 
clinical outcome (44). The trend over time of lysine is 
similar to that of lactic acid and taurine. Lysine is an 
essential amino acid mainly involved as a precursor in 
protein biosynthesis; in addition, lysine is a precursor in the 
biosynthesis of free carnitine and its esterified form 
acylcarnitine, two key metabolites for β-oxidation. In 
hypoxia-ischemia, the decrease of fatty acid oxidation causes 
an increase in carnitines concentrations (45). At birth we 
found very high levels of urinary lysine probably correlated 
with the increasing need of energy source by cells during 
hypoxia. Indeed, lysine can be used as an alternative fuel for 
cells, partially replacing the unavailability of aerobic 
metabolism (46). Subsequently, lysine decreased from T1 to 
T4 as a result of its consumption as a precursor of carnitine. 
It is reasonable to assume that the progressive decrease of 
mannitol over time together with its accumulation in the 
urine of dead babies at T2 (AUC =0.86) may be due to the 
presence of this  metabolic inert substrate within 
pharmaceutical products as excipient (47). Mannitol is a 
carbon non-cyclic sugar alcohol and an isomer of sorbitol 
and can be used in clinical practice to preserve central 
nervous system. Our findings suggest that the decrease of 
mannitol over time is proportional to the reduction in drugs 
administration due to the amelioration of clinical conditions 
especially after TH; conversely, the high level observed in 
dead babies at 72 h may originate from the intensification of 
therapy in critical clinical conditions. Since persistent brain 
hypoxia and ischemia lead to brain hyperosmolality (48), the 
simultaneous increases of mannitol exacerbate the 
process (49). Ultimately, we cannot rule out the presence of 
gut dysbiosis in these babies; in particular Clostridium sp. 
HGF2, Streptococcus sp. M143, Streptococcus sp. M334 
were found to be significantly associated with mannitol (50). 
On the other hand, the dysbiosis-induced hyperpermeability 
of the gut mucosa contributes to the increase of urine 
mannitol excretion (51). Citric acid was found persistently 
increasing from T1 to T4 when compared with T0. Citric 
acid is an intermediate in the TCA cycle. TCA cycle is the 
central metabolic hub of the cell, being the gateway to the 
aerobic metabolism of any molecule that can be transformed 
into an acetyl group or dicarboxylic acid. In addition, TCA 
cycle is a source of precursors for the building blocks of 
amino acids, nucleotide bases, cholesterol, and porphyrin. 
The increase of citric acid over time can be correlated with 
the progressive re-activation of oxygen-dependent ATP 
production pathways, namely the TCA cycle. This is 
confirmed by the finding of citric acid as a discriminant 
metabolite in survivors at 72 h (AUC =0.81). Interestingly, 
in survivors we found high levels of 2-ketoglutaric acid, an 
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intermediate of TCA cycle, both at birth (T0, AUC =0.86) 
and after 72 h (T2, AUC =0.81), strongly supporting the 
assumption that in these babies the aerobic pathways have 
been re-activated and its concomitant absence in dead 
babies. The trend of changes in carbohydrates urine level 
over time is characterized by the decrement of fructose at 
T1 and T2 together with the simultaneous increase of 
lactose and galactose from T1 to T4 and that of galactitol, 
the reduction product of galactose, at T3 and T4 (Figure 4). 
Fructose is metabolized in the liver, primarily to glycogen; 
the accumulation of fructose at birth and the subsequent 
decrease are consistent with the recovery of liver function 
over time. Lactose, a disaccharide of D-glucose and 
D-galactose, is present in milk and is the principal dietary 
source of galactose. Lactose is the primary carbohydrate 
source for developing mammals and in humans it constitutes 
40% of the energy consumed during the nursing period. 
The progressive increase of lactose, galactose, and galactitol 
originates from feeding; in survivors, galactitol was found 
increased both at birth (AUC =0.81) and after 72 h (AUC 
=0.81), while galactose was increased at birth (AUC =0.81). 
4-Hydroxyproline was found increased at T2 and T3. 
L-Proline, a non-essential amino acid synthesized from 
glutamic acid, is an essential component of collagen. The 
enzymatic hydroxylation of proline by prolylhydroxylase 
(PHD) forms hydroxyproline. In hypoxia, hydroxylation of 
proline is involved in targeting hypoxia-inducible factor 
alpha subunit (HIF-1α) by proteolysis (52). HIFs are 
transcription factors responding to changes in available 
oxygen within the cellular environment. The increase over 
time of hydroxyproline may be due to the positive response 
of the organism to the hypoxic condition; conversely, the 
high level of proline in dead babies at birth (AUC =0.76) may 
be considered a negative predictive factor of unfavorable 
outcome for the unavailability of proline hydroxylation and, 
in turn, HIF-1α synthesis. Degradation of 4-hydroxyproline 
results in the formation of glyoxylate; glyoxylate synthesis has 
clinical significance, as it is the only known precursor of 
oxalate. Glyoxylate derived from hydroxyprolin catabolism is 
normally metabolized by alanine: glyoxylate aminotransferase 
(AGT) and glyoxylate reductase (GR); GR plays a significant 
role in metabolizing the glyoxylate derived from 
hydroxyprolin breakdown and limiting its conversion to 
oxalate (53). However, the progressive decrease over time of 
oxalic acid may be due to the utilization of this metabolite for 
the synthesis of uracil and orotic acid (54) that in turn is 
involved in the cellular replication occurring during tissues 
and organs recovery after hypoxia.
Pathway analysis aimed to identify the most involved 
metabolism for each time point. Metabolic pathways 
are groups of metabolites that are related to the same 
biological process, and that are directly or indirectly 
connected by one or multiple enzymatic reactions. All the 
characterizing metabolites were identified and quantified 
by GC-MS and were used to discover the hub and spoke 
within each time point. At birth (Figure 6A), the most 
relevant pathways were the taurine and hypotaurine 
metabolism, tyrosine, and ubiquinone. As detailed 
above, taurine is an intracellular amino acid involved in 
the maintenance of homeostasis in terms of osmolarity 
and promotes the balance of neurotransmitters (55). 
Experimental in vitro studies on human neuroblastoma 
cells demonstrated that taurine exerts a robust protection 
effect against hypoxia and oxygen/glucose deprivation. 
Tyrosine is a non-essential amino acid synthesized in 
mammals from (L)-phenylalanine by phenylalanine 
hydroxylase. Tyrosine is a precursor of neurotransmitters: 
via tyrosine hydroxylase, dopamine can be further 
oxidized to L-norepinephrine that in turn is converted 
in L-epinephrine. Chronic hypoxia/ischemia reduces the 
activity of the enzymes causing neuronal deficiency (56). 
Ubiquinone is a lipid-soluble molecule located in the 
hydrophobic core of the mitochondrial membrane. 
Ubiquinone accepts the electrons both from complex I and 
complex II and then delivers electrons to complex III (57). 
In hypoxic conditions, ubiquinone is implicated in the 
production of ROS even if the role of mitochondrial 
ROS in the regulation of HIF-1 under hypoxia is still 
controversial (58). The remaining relevant metabolisms 
highlighted by the pathway analysis at birth are closely 
correlated with the absolute need of fuel for cellular 
homeostasis, namely glycerolipid, purine, and fatty 
acids metabolisms. At 48 h (Figure 6B), mitochondrial 
dys funct ion and depolar izat ion of  neuronal  ce l l 
membranes take place, leading to the production of ROS, 
whereby hypothermia appears to blunt this response via 
attenuation of oxidative stress. Pathway analysis at 48 
hours reveals an activation of phenylalanine metabolism 
that may be related with neurotransmission; moreover, 
al l  the remaining metabolisms are implied in the 
generation of energetic substrates either via glycolysis 
or gluconeogenesis, or via fatty acid. At the end of the 
TH (Figure 6C), the pyrimidine biosynthesis is the most 
relevant pathway, being of importance for cell proliferation 
and for TCA cycle intermediates. Out of ten metabolisms 
listed as most important in the pathway analysis, eight aim 
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to provide energy to the organism after a period of lactic 
acid overproduction characterized by the depletion of ATP 
for maintaining cell membrane integrity and function. 
Tyrosine metabolism has been previously discussed (48 h). 
The same hubs are present at 1 week (Figure 6D) and at 
1 month (Figure 7) suggesting a metabolic evolution 
towards the recovery by the activation of energetic 
pathways such as the TCA cycle.
Conclusions
Our study is affected by several limitations: the small number 
of newborns, the incomplete set of urine samples over 
time, and the lack of any investigation on gut microbiota 
composition over time. The latter seems to be the most 
important issue for elucidating the origin of a number of 
discriminant metabolites found in our study. However, 
we have extracted a plethora of data by comparing the 
urine metabolome at birth with those observed at each 
time point collection. In particular, we can assume that 
taurine may be considered a candidate biomarker for 
assessing and monitoring cellular injuries and death during 
a hypoxic-anoxic insult. Further investigations including a 
larger number of newborns are required for validating the 
assumption on taurine. Ultimately, it seems of great interest 
to discover in the near future the unknown metabolite U1710 
in order to explain its controversial behavior over time.
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